139 related articles for article (PubMed ID: 9144852)
1. Socioeconomic evaluation of rheumatoid arthritis and osteoarthritis: a literature review.
Rothfuss J; Mau W; Zeidler H; Brenner MH
Semin Arthritis Rheum; 1997 Apr; 26(5):771-9. PubMed ID: 9144852
[TBL] [Abstract][Full Text] [Related]
2. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs.
Lanes SF; Lanza LL; Radensky PW; Yood RA; Meenan RF; Walker AM; Dreyer NA
Arthritis Rheum; 1997 Aug; 40(8):1475-81. PubMed ID: 9259428
[TBL] [Abstract][Full Text] [Related]
3. Assessing cost-effectiveness analyses in rheumatoid arthritis and osteoarthritis.
Ruchlin HS; Elkin EB; Paget SA
Arthritis Care Res; 1997 Dec; 10(6):413-21. PubMed ID: 9481233
[TBL] [Abstract][Full Text] [Related]
4. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls.
Gabriel SE; Crowson CS; Campion ME; O'Fallon WM
J Rheumatol; 1997 Jan; 24(1):43-8. PubMed ID: 9002009
[TBL] [Abstract][Full Text] [Related]
5. The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Haglund U; Svarvar P
Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():51-6. PubMed ID: 11276803
[TBL] [Abstract][Full Text] [Related]
6. Direct medical costs unique to people with arthritis.
Gabriel SE; Crowson CS; Campion ME; O'Fallon WM
J Rheumatol; 1997 Apr; 24(4):719-25. PubMed ID: 9101508
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S
Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490
[TBL] [Abstract][Full Text] [Related]
8. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study.
Maetzel A; Li LC; Pencharz J; Tomlinson G; Bombardier C;
Ann Rheum Dis; 2004 Apr; 63(4):395-401. PubMed ID: 15020333
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of costs in rheumatic diseases: a literature review.
Ruof J; Hülsemann JL; Stucki G
Curr Opin Rheumatol; 1999 Mar; 11(2):104-9. PubMed ID: 10319212
[TBL] [Abstract][Full Text] [Related]
10. The burden of rheumatoid arthritis: facts and figures.
Callahan LF
J Rheumatol Suppl; 1998 Jul; 53():8-12. PubMed ID: 9666412
[TBL] [Abstract][Full Text] [Related]
11. Evidence-based medicine is affordable: the cost-effectiveness of current compared with optimal treatment in rheumatoid and osteoarthritis.
Andrews G; Simonella L; Lapsley H; Sanderson K; March L
J Rheumatol; 2006 Apr; 33(4):671-80. PubMed ID: 16541479
[TBL] [Abstract][Full Text] [Related]
12. [Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis].
Merkesdal S; Ruof J
Z Rheumatol; 2002; 61 Suppl 2():II/29-32. PubMed ID: 12491120
[TBL] [Abstract][Full Text] [Related]
13. Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway.
Svarvar P; Aly A
Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():43-50. PubMed ID: 11276802
[TBL] [Abstract][Full Text] [Related]
14. A reference case for economic evaluations in osteoarthritis: an expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).
Hiligsmann M; Cooper C; Guillemin F; Hochberg MC; Tugwell P; Arden N; Berenbaum F; Boers M; Boonen A; Branco JC; Maria-Luisa B; Bruyère O; Gasparik A; Kanis JA; Kvien TK; Martel-Pelletier J; Pelletier JP; Pinedo-Villanueva R; Pinto D; Reiter-Niesert S; Rizzoli R; Rovati LC; Severens JL; Silverman S; Reginster JY
Semin Arthritis Rheum; 2014 Dec; 44(3):271-82. PubMed ID: 25086470
[TBL] [Abstract][Full Text] [Related]
15. Systematic review of the cost effectiveness of prophylactic treatments in the prevention of gastropathy in patients with rheumatoid arthritis or osteoarthritis taking non-steroidal anti-inflammatory drugs.
van Dieten HE; Korthals-de Bos IB; van Tulder MW; Lems WF; Dijkmans BA; Boers M
Ann Rheum Dis; 2000 Oct; 59(10):753-9. PubMed ID: 11005773
[TBL] [Abstract][Full Text] [Related]
16. Review of health economics modelling in rheumatoid arthritis.
Emery P
Pharmacoeconomics; 2004; 22(2 Suppl 1):55-69. PubMed ID: 15157004
[TBL] [Abstract][Full Text] [Related]
17. An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.
Bansback NJ; Regier DA; Ara R; Brennan A; Shojania K; Esdaile JM; Anis AH; Marra CA
Drugs; 2005; 65(4):473-96. PubMed ID: 15733011
[TBL] [Abstract][Full Text] [Related]
18. Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies.
Huelin R; Pokora T; Foster TS; Mould JF
Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):505-23. PubMed ID: 22971036
[TBL] [Abstract][Full Text] [Related]
19. Addressing obesity in the management of knee and hip osteoarthritis - weighing in from an economic perspective.
Flego A; Dowsey MM; Choong PF; Moodie M
BMC Musculoskelet Disord; 2016 May; 17():233. PubMed ID: 27229924
[TBL] [Abstract][Full Text] [Related]
20. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis.
Furneri G; Mantovani LG; Belisari A; Mosca M; Cristiani M; Bellelli S; Cortesi PA; Turchetti G
Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S72-84. PubMed ID: 23072761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
